The Ebola outbreak in the DRC has claimed more than 3,400 lives and infected thousands more. Despite the scale of the outbreak, there is still no approved vaccine for the latest strain.Leanna Byrne examines what it takes and who pays to develop a vaccine. We look at what's slowing vaccine development and whether the limited commercial market for Ebola vaccines means governments, charities and international donors must step in to fund research.Producer: Matt LinesYou can email the team: <a href="mailto:businessdaily@bbc.co.uk">businessdaily@bbc.co.uk</a>(Picture: Sanitation measures underway at Bunia market to contain Ebola outbreak, Democratic Republic of the Congo - 23 May 2026. Credit: EPA)

Podurama

Home

Trending

Personal

Your Podcasts

New Episodes

My Files

Favourite Episodes

Tags (Folders)

Recently Played

Bookmarks

Followed Playlists

Follow the Money: Why is a new Ebola vaccine taking so long to develop?

Business Daily

AI Chapters

AI Insights

Reviews